Literature DB >> 24381669

5-ARI use in active surveillance: Different paradigm than primary prevention but caution still needed.

Robert James Hamilton1.   

Abstract

Entities:  

Year:  2013        PMID： 24381669      PMCID： PMC3876450          DOI： 10.5489/cuaj.1784

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  4 in total

1.  Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial.

Authors:  Neil E Fleshner; M Scott Lucia; Blair Egerdie; Lorne Aaron; Gregg Eure; Indrani Nandy; Libby Black; Roger S Rittmaster
Journal:  Lancet       Date:  2012-01-24       Impact factor: 79.321

2.  Utility of 5-alpha-reductase inhibitors in active surveillance for favourable risk prostate cancer.

Authors:  Andrew S Chiang; D Andrew Loblaw; Vibhuti Jethava; Perakaa Sethukavalan; Liying Zhang; Danny Vesprini; Alexandre Mamedov; Robert Nam; Laurence Klotz
Journal:  Can Urol Assoc J       Date:  2013 Nov-Dec       Impact factor: 1.862

3.  Intermittent use of testosterone inactivating pharmaceuticals using finasteride prolongs the time off period.

Authors:  Mark C Scholz; Robert I Jennrich; Stephen B Strum; Henry J Johnson; Brad W Guess; Richard Y Lam
Journal:  J Urol       Date:  2006-05       Impact factor: 7.450

4.  Dutasteride treatment over 2 years delays prostate-specific antigen progression in patients with biochemical failure after radical therapy for prostate cancer: results from the randomised, placebo-controlled Avodart After Radical Therapy for Prostate Cancer Study (ARTS).

Authors:  Fritz Schröder; Chris Bangma; Javier C Angulo; Antonio Alcaraz; Marc Colombel; Tom McNicholas; Teuvo L Tammela; Indrani Nandy; Ramiro Castro
Journal:  Eur Urol       Date:  2012-11-12       Impact factor: 20.096
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.